Voya Investment Management LLC Has $73,000 Position in CryoPort, Inc. $CYRX

Voya Investment Management LLC reduced its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX) by 12.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,699 shares during the period. Voya Investment Management LLC’s holdings in CryoPort were worth $73,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Rhumbline Advisers boosted its position in shares of CryoPort by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock valued at $476,000 after acquiring an additional 15,036 shares in the last quarter. Acadian Asset Management LLC boosted its position in CryoPort by 106.4% in the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company’s stock valued at $2,911,000 after buying an additional 247,288 shares in the last quarter. Needham Investment Management LLC boosted its position in CryoPort by 13.7% in the first quarter. Needham Investment Management LLC now owns 277,500 shares of the company’s stock valued at $1,687,000 after buying an additional 33,500 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in CryoPort by 54.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 113,235 shares of the company’s stock valued at $688,000 after buying an additional 39,698 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new position in CryoPort in the first quarter valued at about $369,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CYRX shares. Leerink Partnrs upgraded shares of CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. Stephens started coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price target on the stock. BTIG Research boosted their price target on shares of CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. Leerink Partners upgraded shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Wednesday, August 6th. Finally, KeyCorp upgraded shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target on the stock in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, CryoPort currently has a consensus rating of “Buy” and an average price target of $12.56.

CryoPort Stock Up 0.2%

Shares of NASDAQ:CYRX opened at $9.50 on Thursday. CryoPort, Inc. has a 52 week low of $4.58 and a 52 week high of $10.46. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The company has a market capitalization of $475.67 million, a PE ratio of 7.14 and a beta of 1.61. The company has a 50 day moving average price of $8.77 and a two-hundred day moving average price of $7.21.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Insider Buying and Selling

In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the company’s stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the sale, the director directly owned 92,328 shares of the company’s stock, valued at approximately $668,454.72. This represents a 30.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at $1,796,536.71. The trade was a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 80,028 shares of company stock worth $661,252. 10.00% of the stock is owned by insiders.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.